Basic fibroblast growth factor reduces functional and structural damage in chronic kidney disease

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 4, 2014, Pages

  Villanueva, Sandra ^a   Contreras, Felipe ^a   Tapia, Andrés ^a   Carreño, Juan E ^a   Vergara, Cesar ^a   Ewertz, Ernesto ^a   Cespedes, Carlos ^b   Irarrazabal, Carlos ^a   Sandoval, Mauricio ^a   Velarde, Victoria ^b   Vio, Carlos P ^b  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

bFGF; Chronic kidney disease; Renal recovery

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN RECEPTOR; COLLAGEN; CREATININE; FIBROBLAST GROWTH FACTOR 2; LIM PROTEIN; LIM1 PROTEIN; NERVE CELL ADHESION MOLECULE; NOGGIN; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOGENIC PROTEIN 1; SMAD PROTEIN; TRANSCRIPTION FACTOR PAX2; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT4 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; FUNCTIONAL ASSESSMENT; KIDNEY CELL; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY INTERSTITIUM; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RENAL STEM CELL; STEM CELL; TISSUE REPAIR;

BFGF; CHRONIC KIDNEY DISEASE; RENAL RECOVERY;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CREATININE; FIBROBLAST GROWTH FACTOR 2; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY; MALE; NEPHRECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, TIE-2; RENAL INSUFFICIENCY, CHRONIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84894094465     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00720.2012     Document Type: Article

References (55)

1. Abbate M, Brown D, Bonventre J. Expression of NCAM recapitulates tubulogenic development in kidneys recovering from acute ischemia. Am J Physiol Renal Physiol 277: F454-463, 1999.
2. Barasch J, Qiao J, McWilliams G, Chen D, Oliver JA, Herzlinger D. Ureteric bud cells secrete multiple factors, including bFGF, which rescue renal progenitors from apoptosis. Am J Physiol Renal Physiol 273: F757-F767, 1997.
3. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8: R204-R212, 2004.
4. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114: 521-532, 1992.
5. Brunet LJ, McMahon JA, McMahon AP, Harland RM. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455-1457, 1998.
6. Cai Q, Dmitrieva N, Ferraris J, Brooks H, van Balkom B, Burg M. Pax2 expression occurs in renal medullary epithelial cells in vivo and in cell culture, is osmoregulated, and promotes osmotic tolerance. Proc Natl Acad Sci USA 102: 503-508, 2005.
7. Chen L, Endler A, Shibasaki F. Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp Mol Med 41: 849-857, 2009.
8. Colleoni S, Bottani E, Tessaro I, Mari G, Merlo B, Romagnoli N, Spadari A, Galli C, Lazzari G. Isolation, growth and differentiation of equine mesenchymal stem cells: effect of donor, source, amount of tissue and supplementation with basic fibroblast growth factor. Vet Res Commun 33: 811-821, 2009.
9. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH. Chronic kidney disease awareness, prevalence and trends among US adults, 1999 to 2000. J Am Soc Nephrol 16: 180-188, 2005.
10. DiRocco DP, Kobayashi A, Taketo MM, McMahon AP, Humphreys BD. Wnt4/fj-catenin signaling in medullary kidney myofibroblasts. JASN 24: 1399-1412, 2013.
11. Dudley AT, Godin RE, Robertson EJ. Interaction between FGF and BMP signaling pathways regulates development of metanephric mesenchyme. Genes Dev 13: 1601-1613, 1999.
12. Dudley AT, Lyons KM, Robertson EJ. A requirement for bone mor-phogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 9: 2795-2807, 1995.
13. Fleck C, Appenroth D, Jonas P, Koch M, Kundt G, Nizze H, Stein G. Suitability of 5/6 nephrectomy (5/6NX) for the induction of interstitial renal fibrosis in rats-influence of sex, strain, and surgical procedure. Exp Toxicol Pathol 57: 195-205, 2006.
14. Galle J. Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med 5: S36-S43, 2008.
15. Goda N, Dozier SJ, Johnson RS. HIF-1 in cell cycle regulation, apopto-sis, and tumor progression. Antioxid Redox Signal 5: 467-473, 2003.
16. Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol 20: 1877-1887, 2009.
17. Gupta S, Verfaillie C, Chmielewski D, Kren S, Eidman K, Connaire J, Heremans Y, Lund T, Blackstad M, Jiang Y, Luttun A, Rosenberg ME. Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol 17: 3028-3040, 2006.
18. Imgrund M, Grone E, Grone HJ, Kretzler M, Holzman L, Schlon-dorff D, Rothenpieler UW. Re-expression of the developmental gene Pax-2 during experimental acute tubular necrosis in mice. Kidney Int 56: 1423-1431, 1999.
19. Karanova I, Dove L, Resau J, Perantoni A. Conditioned medium from a rat ureteric bud cell line in combination with bFGF induces complete differentiation of isolated metanephric mesenchyme. Development 122: 4159-4167, 1996.
20. Kaspar DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS, Editors. Harrison Principios de Medicina Interna. New York: McGraw-Hill, 2007.
21. Kelly DJ, Hepper C, Wu LL, Cox AJ, Gilbert RE. Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model. Nephrol Dial Transplant 18: 1286-1292, 2003.
22. Kim BS, Goligorsky MS. Role of VEGF in kidney development, micro-vascular maintenance and pathophysiology of renal disease. Korean J Intern Med 18: 65-75, 2003.
23. Kolatsi-Joannou M, Li XZ, Suda T, Yuan IT, Woolf AS. Expression and potential role of angiopoietins and Tie-2 in early development of the mouse metanephros. Dev Dyn 222: 120-126, 2001.
24. Kopp JB. BMP receptors in kidney. Kidney Int 58: 2237-2238, 2000.
25. Lackie PM, Zuber C, Roth J. Polysialic acid and N-CAM localisation in embryonic rat kidney: mesenchymal and epithelial elements show different patterns of expression. Development 110: 933-947, 1990.
26. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, Quyyumi AA. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 36: 1239-1244, 2000.
27. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, White-house MJ, Annex BH. Therapeutic angiogenesis with recombinant fibro-blast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359: 2053-2058, 2002.
28. Lemiere S, Azar R, Belloc F, Gürsel D, Pyronnet S, Bikfalvi A, Auguste P. Overexpression of high molecular weight FGF-2 forms inhibits glioma growth by acting on cell-cycle progression and protein translation. Exp Cell Res 314: 3701-3711, 2008.
29. Manotham K, Tanaka T, Ohse T, Kojima I, Miyata T, Inagi R, Tanaka H, Sassa R, Fujita T, Nangaku M. A biologic role of HIF-1 in the renal medulla. Kidney Int 67: 1428-1439, 2005.
30. Miyamoto K, Kitamoto Y, Tokunaga H, Takeya M, Ezaki T, Ima-mura T, Tomita K. Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat. Lab Invest 84: 1126-1136, 2004.
31. Naito T, Ma LJ, Yang H, Zuo Y, Tang Y, Han JY, Kon V, Fogo AB. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Renal Physiol 298: F683-F691, 2010.
32. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med 43: 9-17, 2004.
33. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4: 542-551, 2009.
34. Pedersen A, Skjong C, Shawlot W. Lim 1 is required for nephric duct extension and ureteric bud morphogenesis. Dev Biol 288: 571-581, 2005.
35. Pitera JE, Woolf AS, Gale NW, Yancopoulos GD, Yuan HT. Dysmor-phogenesis of kidney cortical peritubular capillaries in angiopoietin-2-deficient mice. Am J Pathol 165: 1895-1906, 2004.
36. Rabie AB, Lu M. Basic fibroblast growth factor up-regulates the expression of vascular endothelial growth factor during healing of allogeneic bone graft. Arch Oral Biol 49: 1025-1033, 2004.
37. Rieck PW, Gigon FM, Jaroszewski J, Pleyer U, Hartmann C. Increased endothelial survival of organ-cultured corneas stored in FGF-2-supplemented serum-free medium. Invest Ophtalmol Vis Sci 44: 3826-3832, 2003.
38. Ripley E. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease. Am Heart J 157: S7-S10, 2009.
39. Rogelj S, Klagsbrun M, Atzmon R, Kurokawa M, Haimovitz A, Fuks Z, Vlodavsky I. Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothe-lial cells and the differentiation of PC 12 cells. J Cell Biol 109: 823-831, 1989.
40. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721-1732, 2002.
41. Rothenpieler UW, Dressler GR. Pax-2 is required for mesenchyme-to-epithelium conversion during kidney development. Development 119: 711-720, 1993.
42. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107: 743-751, 1998.
43. Sengul E, Sahin T, Sevin E, Yilmaz A. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease. Ren Fail 31: 928-932, 2009.
44. Shi YH, Bingle L, Gong LH, Wang YX, Corke KP, Fang WG. Basic FGF augments hypoxia induced HIF-1alpha expression and VEGF release in T47D breast cancer cells. Pathology 39: 396-400, 2007.
45. Singri N, Ahya SN, Levin ML. Acute renal failure. JAMA 289: 747-751, 2003.
46. Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 85: 1414-1419, 2000.
47. Villanueva S, Cespedes C, Gonzalez AA, Roessler E, Vio CP. Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses neph-rogenic protein expression after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 294: R819-R828, 2008.
48. Villanueva S, Cespedes C, González A, Vio CP. bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 291: R1677-R1687, 2006.
49. Villanueva S, Cespedes C, Vio CP. Ischemic acute renal failure induces the expression of a wide range of nephrogenic proteins. Am J Physiol Regul Integr Comp Physiol 290: R861-R870, 2006.
50. Villanueva S, Glavic A, Ruiz P, Mayor R. Posteriorization by FGF, Wnt and retinoic acid is required for neural crest induction. Dev Biol 241: 289-301, 2002.
51. Vio CP, An SJ, Cespedes C, McGiff JC, Ferreri NR. Induction of cyclooxygenase-2 in thick ascending limb cells by adrenalectomy. J Am Soc Nephrol 12: 649-658, 2001.
52. Vio CP, Cespedes C, Gallardo P, Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 30: 687-692, 1997.
53. Vrljicak P, Myburgh D, Ryan AK, Van Rooijen MA, Mummery CL, Gupta IR. Smad expression during kidney development. Am J Physiol Renal Physiol 286: F625-F633, 2004.
54. Wagner KD, Wagner N, Wellmann S, Schley G, Bondke A, Theres H, Scholz H. Oxygen-regulated expression of the Wilms tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J 171: 364-1366, 2003.
55. Witzgall R, Brown D, Schwarz C, Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogeneous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 93: 2175-2188, 1994.